Expertise in
20
conditions

Dr. Kelly L. Stratton

Urology
800 N.E. 10th St., Suite 4300, 
Oklahoma City, OK 
Accepting New Patients
Offers Telehealth
Expertise in
20
conditions
800 N.E. 10th St., Suite 4300, 
Oklahoma City, OK 

Overview

Kelly Stratton is a Urologist practicing medicine in Oklahoma City, Oklahoma.

Dr. Stratton is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Prostate Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery.

Dr. Stratton is board certified in American Board Of Urology , Oklahoma State Board Of Medical Licensure & Supervision, Drug Enforcement Administration , and Oklahoma Bureau Of Narcotics And Dangerous Drugs . He is actively involved in clinical research, co-authoring 53 peer reviewed articles and participating in 15 clinical trials. Dr. Stratton is currently accepting new patients.

Specialties

Urology

Licenses

Urology in NY

Board Certifications

American Board Of Urology
Oklahoma State Board Of Medical Licensure & Supervision
Drug Enforcement Administration
Oklahoma Bureau Of Narcotics And Dangerous Drugs

Fellowships

Memorial Sloan Kettering Cancer Institute

Hospital Affiliations

SSM Health St. Anthony Hospital - Oklahoma City
Duncan Regional Hospital, Inc
Integris Baptist Medical Center, Inc
Ssm Health St Anthony Hospital - Shawnee
Ssm Health St Anthony Hospital - Oklahoma City
O U Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

GlobalHealth
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

800 N.E. 10th St., Suite 4300, Oklahoma City, OK 73104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Sinecatechins
Study Phase: Phase 2
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Atezolizumab, Cisplatin, Fluorouracil, Gemcitabine, Mitomycin C
Study Phase: Phase 3
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
A Phase III Double Blinded Study of Early Intervention After RADICAl ProstaTEctomy With Androgen Deprivation Therapy With or Without Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2026
Intervention Type: Other, Drug
Study Drugs: Darolutamide, Goserelin acetate, Leuprolide acetate, Triptorelin
Study Phase: Phase 3
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Surgery in Early Metastatic Seminoma (SEMS): Phase II Trial of Retroperitoneal Lymph Node Dissection as First-Line Treatment for Testicular Seminoma With Isolated Retroperitoneal Disease (1-3cm)
Enrollment Status: Active_not_recruiting
Publish Date: June 09, 2026
Intervention Type: Procedure, Other
Study Phase: Not Applicable
An Observational Study of Efficacy and Utility of Cxbladder Tests in the Identification of Low vs High Risk Patients and the Detection of Urothelial Carcinoma in Patients Presenting With Hematuria
An Observational Study of Efficacy and Utility of Cxbladder Tests in the Identification of Low vs High Risk Patients and the Detection of Urothelial Carcinoma in Patients Presenting With Hematuria
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Diagnostic test
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: March 12, 2026
Intervention Type: Procedure, Other
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: December 31, 2025
Intervention Type: Drug
Study Drugs: TAK-700, Bicalutamide
Study Phase: Phase 3
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
A Randomized Controlled Trial Of AdV-tk + Valacyclovir Administered During Active Surveillance For Newly Diagnosed Prostate Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Biological, Drug
Study Drugs: Aglatimagene Besadenovec, Valacyclovir
Study Phase: Phase 2
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
View 9 Less Clinical Trials

53 Total Publications

Management of Inflammatory Myofibroblastic Tumor of Urinary Bladder With Partial Cystectomy: A Case Report.
Management of Inflammatory Myofibroblastic Tumor of Urinary Bladder With Partial Cystectomy: A Case Report.
Journal: Cureus
Published: June 26, 2026
Similar Doctors
Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required
800 N.E. 10th St., Suite 4300, 
Oklahoma City, OK 
 (0.1 miles away)
405-271-4088
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael Cookson is a Urologist practicing medicine in Oklahoma City, Oklahoma. Dr. Cookson is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, Cystectomy, and Nephrectomy. Dr. Cookson is board certified in American Board Of Urology , Oklahoma State Board Of Medical Licensure & Supervision, Drug Enforcement Administration , and Oklahoma Bureau Of Narcotics And Dangerous Drugs . Dr. Cookson is currently accepting new patients.

Expertise in
22
conditions
Expertise in
22
conditions
Referral may be required

OU Health Stephenson Cancer Center At The University Of Oklahoma Health Sciences - Prostate & Urolog

800 NE 10th St # 4300, 
Oklahoma City, OK 
 (0.4 miles away)
405-271-4088
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sanjay Patel is a Urologist practicing medicine in Oklahoma City, Oklahoma. Dr. Patel is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Non-Muscle Invasive Bladder Cancer, Nephrectomy, and Cystectomy. Dr. Patel is currently accepting new patients.

Expertise in
20
conditions
Expertise in
20
conditions
Referral may be required

Ou Health Physicians-Urology Clinic

825 NE 10th St # 5F, 
Oklahoma City, OK 
 (0.4 miles away)
572-244-0071
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gennady Slobodov is a Urologist practicing medicine in Oklahoma City, Oklahoma. Dr. Slobodov is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Neurogenic Bladder, Urinary Incontinence, Urinary Tract Infection in Children, Ureteroscopy, and Sacral Nerve Stimulation. Dr. Slobodov is currently accepting new patients.

Frequently Asked Questions about Dr. Kelly L. Stratton

How do I make an appointment with Dr. Kelly L. Stratton?

You can book an appointment with Dr. Kelly L. Stratton by calling their office at 405-271-4088. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kelly L. Stratton a top-rated expert for Bladder Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kelly L. Stratton is classified as an Distinguished expert for Bladder Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kelly L. Stratton specialize in?

While Dr. Kelly L. Stratton is a Urology, they have specific expertise in Bladder Cancer, Prostate Cancer, and Non-Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Urology.

Does Dr. Kelly L. Stratton participate in research or clinical trials?

Yes. Dr. Kelly L. Stratton has published 53 articles and abstracts on conditions like Bladder Cancer. You can view a list of Dr. Kelly L. Stratton's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kelly L. Stratton accept my insurance?

Dr. Kelly L. Stratton accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 405-271-4088 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stratton's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 13 Advanced Conditions
    View All 27 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile